Infectious Diseases
With one of the most advanced clinical testing laboratories of oncology and depression patients in the country, and the ability to process >1 million samples each year, Tempus is uniquely situated to extend testing capabilities to infectious diseases, starting with COVID-19.
UNDERSTANDING THE NEW NORMAL
As we return to “normal,” we need a system to determine who has COVID-19 versus other viral infections that have similar symptoms, while simultaneously gathering relevant data about the underlying genetics of these diseases.
Symptomatic patients face difficulty getting tests, carriers can be asymptomatic for several weeks, and we still don’t understand the clinical and genetic hallmarks of COVID-19 and similar infectious diseases. Tempus is committed to supporting the care of COVID-19 patients through testing and collecting the appropriate data to understand the disease at a greater level.
of patients were largely asymptomatic with COVID-19 in two independent studies 1 2
COVID-19 Offerings
Leveraging testing and clinical data against COVID-19
We are committed to using our advanced testing and analytics capabilities to support care management for COVID-19
- PCR testing for real-time COVID-19 detection
- Research program for data collection and whole transcriptome analysis
- Next-Generation Sequencing for COVID-19 and other respiratory pathogens
PCR Testing
Testing for real-time COVID-19 detection
Leveraging our existing testing capabilities, we’ve launched a diagnostic reverse transcription polymerase chain reaction (RT-qPCR) assay for COVID-19. PCR testing is one of the few testing options authorized by the FDA to detect and track the spread of COVID-19.
It’s critical to act swiftly in the face of the COVID-19 pandemic and Tempus is committed to expanding lab capacity to test thousands of patients a day for COVID-19.
We offer customized programs based on different testing needs between organizations, agencies, and employers.
- Test eligibility: Individual patients can request a COVID-19 test through their own medical professional, or via Tempus’ telemedicine partner.
- Sample kits are provided to you to be administered onsite by a healthcare professional.
- Sample kits are collected daily and processed by Tempus.
- Results are typically returned in ~2 days via the Tempus patient mobile application.
- Patient consultation with their own physician or a Tempus’ telemedicine partner.
TEMPUS|iD
Next-generation sequencing for COVID-19 and other respiratory pathogens
Building upon our next-generation sequencing infrastructure, Tempus is validating a comprehensive sequencing panel (Tempus|iD) which will cover a broad range of known respiratory ailments including COVID-19 and other common forms of coronavirus, pneumonia, influenza, rhinovirus, etc.
By differentiating whether a patient’s infection is caused by COVID-19 or a different strain of virus, and by providing consensus guidance for treatment and therapy, clinical decisions can be made with more complete information.
Additionally, the Tempus|iD panel returns a broader range of genomic sequencing for the virus, enabling further research and discovery.
Tempus|iD coming soon.
COVID-19 RESEARCH INITIATIVES
Research program for data collection and whole transcriptome analysis
We are supporting the fight against COVID-19 by rapidly collecting and curating patient clinical data as well as performing full RNA transcriptome research sequencing for thousands of patients at no cost to institutions or patients.
We will collect clinical data for COVID-19 patients and apply our data abstraction expertise to structure a variety of record types and formats, helping researchers understand treatment and response patterns for patients battling the novel coronavirus.
Clinical data includes demographic information, symptoms, observations, and clinical notes, treatment and therapy history, and outcomes and results data.
By combining this clinical data with rich RNA sequencing data, Tempus will collaborate with research partners to advance research and discovery related to COVID-19.
Learn more about our work in infectious diseases.
Contact Us1. Source: Reuters. U.S. to Start Antibody Testing of Sailors on Coronavirus-Hit Aircraft Carrier. April 17, 2020.
2. Source: Mass General Hospital. COVID-19 outbreak at a large homeless shelter in Boston: Implications for universal testing. April 15, 2020.